Pancreatic Cancer's PD1-Roadblock: When T-Cell Reinvigoration Is Not Enough.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 38038687.
- Also identified by DOI 10.1158/1078-0432.CCR-23-2991 and PMC identifier 10842790.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
PD1-blockade combinations in pancreatic ductal adenocarcinoma have been poorly effective, and the underlying reasons for this are unknown. A recent study revealed that chemoradiation plus PD1-blockade reinvigorates tumor-specific T cells; however, this T-cell activation is accompanied with exaggerated NFκB signaling, which may limit productive tumor-controlling immunity. See related article by Ali et al., p. 542.
Medical subject headings
- Pancreatic Neoplasms
- Carcinoma, Pancreatic Ductal